

MSHP 2021 Clinical Integration Program Quality Performance Metrics Internal & Family Medicine Tip Sheet

Breast Cancer Screening*

Denominator:	Numerator:
Patients 50 to 74 years of age at the beginning of the measurement period AND patient encounter during the performance period.	Women with one or more mammograms during the 27 months prior to the end of the measurement period.

Colorectal Cancer Screening*

Denominator:	Numerator:
Patients 50 to 75 years of age on date of encounter AND Patient encounter during the performance period.	<p>Patients with one or more screenings for colorectal cancer.</p> <ul style="list-style-type: none"> - Fecal occult blood test (FOBT) during the measurement period. - Flexible sigmoidoscopy during the measurement period or the 4 years prior. - Colonoscopy during the measurement period or the 9 years prior. - Computed tomography (CT) colonography during the measurement period or the 4 years prior. - Fecal immunochemical DNA test (FIT-DNA) during the measurement period or the 2 years prior to the measurement period.

Percent of Panel with PCP visit (telehealth or in person by 8/31/2021)

Denominator:	Numerator:
Adult patients attributed to a provider in a value-based contract.	<p>Preventive Medicine Services:</p> <p><i>Medicare AWV</i></p> <ul style="list-style-type: none"> - IPPE - G402 - Initial AWV - G0438 - Subsequent AWV - G0439 <p><i>New Patients</i></p> <ul style="list-style-type: none"> - Age 18 – 39 - 99385 - Age 40 – 64 - 99386 - Complete Physical Exams or Well Checks for 65 and older - 99387 <p><i>Established Patients</i></p> <ul style="list-style-type: none"> - Age 18 – 39 years - 99395 - Age 40 - 64 years - 99396 - 65 years and older - 99397

	<p>E&M Visits:</p> <p><i>New Patient</i></p> <ul style="list-style-type: none"> - Level 2 – 99202 - Level 3 – 99203 - Level 4 – 99204 - Level 5 – 99205 <p><i>Established Patient</i></p> <ul style="list-style-type: none"> - Level 1 – 99211 - Level 2 – 99212 - Level 3 – 99213 - Level 4 – 99214 - Level 5 – 99215
Diabetes: Hemoglobin A1c (HbA1c) Test*	
<p>Denominator: Patients 18 through 75 years of age on date of encounter <u>AND</u> Diagnosis for diabetes <u>AND</u> patient encounter during performance period</p>	<p>Numerator: Patients with HbA1c test completed in 2021.</p>
	<p>Diabetes: Eye Exam*</p> <p>Denominator: Patients 18 to 75 years of age on date of encounter <u>AND</u> Diagnosis for diabetes (ICD-10-CM) <u>AND</u> patient encounter during the performance period</p> <p>Numerator: Diabetics with an eye screening for diabetic retinal disease who had one of the following:</p> <ul style="list-style-type: none"> - Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed (G2102) - Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist documented and reviewed (G2103) - Eye imaging validated to match diagnosis from seven standard field stereoscopic photos results documented and reviewed (G2104) - Low risk for retinopathy (no evidence of retinopathy in the prior year)* (CPT II code 3072F)
Diabetes: Medical Attention for Nephropathy*	
<p>Denominator: Patients aged 18 years to 75 years on date of encounter <u>AND</u> Diagnosis for diabetes (ICD-10) <u>AND</u> patient encounter during the performance period</p>	<p>Numerator: Patients with a screening for nephropathy or evidence of nephropathy during the measurement period:</p> <ul style="list-style-type: none"> - A urine test for albumin or protein. At a minimum, documentation must include a note indicating the date when a urine test was performed, and the result or finding. <p>Any of the following meet the criteria:</p> <ul style="list-style-type: none"> - 24-hour urine for albumin or protein

	<ul style="list-style-type: none"> - Timed urine for albumin or protein - Spot urine (e.g., urine dipstick or test strip) for albumin or protein - Urine for albumin/creatinine ratio - 24-hour urine for total protein - Random urine for protein/creatinine ratio - Documentation of treatment for nephropathy (e.g., patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist) (3066F) - Documentation that a prescription for an ACE inhibitor/ARB was filled during the measurement year
Medication Adherence for Diabetes Medications	
<p>Denominator: Number of patients with at least two fills of diabetes medication(s) on unique dates of service during the measurement period.</p>	<p>Numerator: Number of patients with a proportion of days covered (PDC) at 80 percent or higher across the classes of diabetes medications during the measurement period.</p>
<p>Measure description:</p> <ul style="list-style-type: none"> - Percent of plan members with a prescription for diabetes medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. - Diabetes medication means a biguanide drug, a sulfonylurea drug, a thiazolidinedione drug, a DPP-IV inhibitor, an incretin mimetic drug, a meglitinide drug, or an SGLT2 inhibitor. Patients who take insulin are not included. 	
Medication Adherence for Cholesterol (Statins)	
<p>Denominator: Number of patients with at least two statin cholesterol medication fills on unique dates of service during the measurement period.</p>	<p>Numerator: Number of patients with a proportion of days covered (PDC) at 80 percent or higher for statin cholesterol medication(s) during the measurement period.</p>
<p>Measure description:</p> <ul style="list-style-type: none"> - Patients with a prescription for a cholesterol medication (a statin drug) who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. - Statins include: atorvastatin (+/- amlodipine, ezetimibe), fluvastatin, lovastatin (+/- niacin), pitavastatin, pravastatin, rosuvastatin, simvastatin (+/- ezetimibe, niacin, sitagliptin) 	
Medication Adherence for Hypertension (RAS antagonists)	
<p>Denominator: Number of patients with at least two blood pressure medications fills on unique dates of service during the measurement period.</p>	<p>Numerator: Number of patients with a proportion of days covered (PDC) at 80 percent or higher for RAS antagonist medications during the measurement period.</p>

2021 Quality Reporting Metrics

Internal & Family Medicine Tip Sheet

Percent of Medicare Advantage members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication.

Blood pressure medication means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.

ARBs:	ACE Inhibitors:	Direct Renin Inhibitor
azilsartan (+/- chlorthalidone) candesartan (+/- hydrochlorothiazide) eprosartan (+/- hydrochlorothiazide) irbesartan (+/- hydrochlorothiazide) losartan (+/- hydrochlorothiazide) olmesartan (+/- amlodipine, hydrochlorothiazide) telmisartan (+/- amlodipine, hydrochlorothiazide) valsartan (+/- amlodipine, hydrochlorothiazide nebivolol)	benazepril (+/- amlodipine, hydrochlorothiazide) captopril (+/- hydrochlorothiazide) enalapril (+/- hydrochlorothiazide) fosinopril (+/- hydrochlorothiazide) lisinopril (+/- hydrochlorothiazide) moexipril (+/- hydrochlorothiazide) perindopril (+/- amlodipine) quinapril (+/- hydrochlorothiazide) ramipril trandolapril (+/- verapamil)	aliskiren (+/- amlodipine, hydrochlorothiazide)

*Please refer to the following link for the full measure descriptions:

https://mshp.mountsinai.org/web/mshp/for-providers/quality/quality-measure-descriptions/internal-medicine-outpatient_family-medicine